JP2023530278A - タンデムアネロウイルス構築物 - Google Patents

タンデムアネロウイルス構築物 Download PDF

Info

Publication number
JP2023530278A
JP2023530278A JP2022576004A JP2022576004A JP2023530278A JP 2023530278 A JP2023530278 A JP 2023530278A JP 2022576004 A JP2022576004 A JP 2022576004A JP 2022576004 A JP2022576004 A JP 2022576004A JP 2023530278 A JP2023530278 A JP 2023530278A
Authority
JP
Japan
Prior art keywords
anellovirus
nucleic acid
sequence
orf1
genetic element
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530278A5 (cg-RX-API-DMAC10.html
Inventor
サイモン デラグレイブ,
ケビン ジェイムズ レボ,
ダナンジャイ マニクラール ナワンダル,
ジョセフ ルイス ティンポナ,
Original Assignee
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド filed Critical フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド
Publication of JP2023530278A publication Critical patent/JP2023530278A/ja
Publication of JP2023530278A5 publication Critical patent/JP2023530278A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2022576004A 2020-06-12 2021-06-11 タンデムアネロウイルス構築物 Pending JP2023530278A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063038483P 2020-06-12 2020-06-12
US63/038,483 2020-06-12
US202163146963P 2021-02-08 2021-02-08
US63/146,963 2021-02-08
PCT/US2021/037091 WO2021252955A1 (en) 2020-06-12 2021-06-11 Tandem anellovirus constructs

Publications (2)

Publication Number Publication Date
JP2023530278A true JP2023530278A (ja) 2023-07-14
JP2023530278A5 JP2023530278A5 (cg-RX-API-DMAC10.html) 2024-06-18

Family

ID=78845951

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576004A Pending JP2023530278A (ja) 2020-06-12 2021-06-11 タンデムアネロウイルス構築物

Country Status (12)

Country Link
US (1) US20230348933A1 (cg-RX-API-DMAC10.html)
EP (1) EP4165198A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023530278A (cg-RX-API-DMAC10.html)
KR (1) KR20230036110A (cg-RX-API-DMAC10.html)
CN (1) CN116075591A (cg-RX-API-DMAC10.html)
AU (1) AU2021288320A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022025190A2 (cg-RX-API-DMAC10.html)
CA (1) CA3186894A1 (cg-RX-API-DMAC10.html)
IL (1) IL298978A (cg-RX-API-DMAC10.html)
MX (1) MX2022015802A (cg-RX-API-DMAC10.html)
TW (1) TW202223095A (cg-RX-API-DMAC10.html)
WO (1) WO2021252955A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121528A1 (en) 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
WO2025160409A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Viral vectors for modulating vegf function
CN119331914A (zh) * 2024-10-17 2025-01-21 中科开浦生物科技(湖北)有限公司 一种指环病毒感染性克隆的构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502229A (ja) * 2009-08-21 2013-01-24 ヴァージニア テック インテレクチュアル プロパティーズ,インコーポレーテッド 豚トルクテノウイルスワクチンおよび診断
JP2018535251A (ja) * 2015-10-16 2018-11-29 カンザス ステイト ユニバーシティ リサーチ ファウンデーション ブタサーコウイルス3型免疫原性組成物、その製造方法、およびその使用方法
WO2018232017A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering, Inc. Compositions comprising curons and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593189B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
ES2777217T3 (es) * 2013-06-17 2020-08-04 Broad Inst Inc Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
CA3121528A1 (en) * 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes and methods of use
JP2022513459A (ja) * 2018-12-12 2022-02-08 フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド タンパク質代替治療モダリティを送達するためのアネロソーム
EP3894567A2 (en) * 2018-12-12 2021-10-20 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering intracellular therapeutic modalities

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502229A (ja) * 2009-08-21 2013-01-24 ヴァージニア テック インテレクチュアル プロパティーズ,インコーポレーテッド 豚トルクテノウイルスワクチンおよび診断
JP2018535251A (ja) * 2015-10-16 2018-11-29 カンザス ステイト ユニバーシティ リサーチ ファウンデーション ブタサーコウイルス3型免疫原性組成物、その製造方法、およびその使用方法
WO2018232017A1 (en) * 2017-06-13 2018-12-20 Flagship Pioneering, Inc. Compositions comprising curons and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY, vol. 78, no. 19, JPN6025021007, 2004, pages 10820 - 10824, ISSN: 0005602044 *
PLOS PATHOGENS, vol. 9, no. 12, JPN6025021006, 2013, pages 1003818, ISSN: 0005735472 *

Also Published As

Publication number Publication date
IL298978A (en) 2023-02-01
WO2021252955A1 (en) 2021-12-16
MX2022015802A (es) 2023-03-28
US20230348933A1 (en) 2023-11-02
CN116075591A (zh) 2023-05-05
KR20230036110A (ko) 2023-03-14
EP4165198A4 (en) 2024-10-23
TW202223095A (zh) 2022-06-16
AU2021288320A1 (en) 2023-01-19
EP4165198A1 (en) 2023-04-19
BR112022025190A2 (pt) 2023-03-07
CA3186894A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
US20220362315A1 (en) Anellovirus compositions and methods of use
US20260009050A1 (en) Anellosomes for delivering secreted therapeutic modalities
WO2018232017A1 (en) Compositions comprising curons and uses thereof
AU2019396516B2 (en) Anellosomes for delivering intracellular therapeutic modalities
JP2024099834A (ja) アネロソーム及び使用の方法
JP2024099833A (ja) タンパク質代替治療モダリティを送達するためのアネロソーム
JP2023530277A (ja) バキュロウイルス発現系
AU2021288320A1 (en) Tandem anellovirus constructs
JP2023530451A (ja) アネロウイルスを同定し及び特徴付ける方法並びにその使用
JP2023548838A (ja) ニワトリ貧血ウイルス(cav)に基づくベクター
US20240254512A1 (en) Anellovectors and methods of use
JP2024507732A (ja) ハイッブリッドaav-アネロベクター
CN116829723A (zh) 基于鸡贫血病毒(cav)的载体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250526

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251120